Alivio Therapeutics Inc., a Boston-based affiliate of Puretech Health plc, secured a $3.3 million Department of Defense Technology/Therapeutic Development Award to advance ALV-107 for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.